Federal Circuit Discusses a Myriad of Patent-Eligibility Issues
Our colleagues George Snyder and Rob Browne have written a detailed analysis, which can be found here, of last week's decision by the Federal Circuit that certain isolated human DNA molecules are eligible for patent protection. The Association of Molecular Pathology et al. v. United States Patent and Trademark Office, and Myriad Genetics, Inc., No. 2010-1406 (Fed. Cir. July 29, 2011). This was an important decision because the patenting of isolated DNA molecules has broad commercial value to the growing biotech industry.
